Jehonathan Pinthus
Overview
Explore the profile of Jehonathan Pinthus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
503
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leong D, Fradet V, Niazi T, Selvanayagam J, Sabbagh R, Higano C, et al.
JACC CardioOncol
. 2024 Oct;
6(5):761-771.
PMID: 39479325
Background: There are limited data on the physical effects of androgen deprivation therapy (ADT) for prostate cancer (PC), and on the relationships of such measures of adiposity and strength to...
2.
Dahan J, Pinthus J, Delouya G, Taussky D, Duceppe E, de Jesus A, et al.
BMC Urol
. 2024 Oct;
24(1):226.
PMID: 39407194
Introduction: Several blood markers of inflammation are elevated in prostate cancer (PCa) and have prognostic value. Little is known about the relationship between these markers, PCa, and other factors associated...
3.
Cirne F, Mukherjee S, Pinthus J, Leong D
Isr Med Assoc J
. 2022 Mar;
24(3):175-178.
PMID: 35347931
Increased life expectancy due to improved cancer prognosis, shared determinants (e.g., tobacco use), and cardiovascular toxicities related to cancer therapies, including the adverse cardiometabolic effects of androgen deprivation therapy for...
4.
Savija N, Leong D, Pinthus J, Karampatos S, Shayegan B, Mian R, et al.
Curr Dev Nutr
. 2021 Dec;
5(11):nzab106.
PMID: 34870071
Background: There are few concise tools to evaluate dietary habits in men with prostate cancer in Canada. Objective: The aim was to develop a short food-frequency questionnaire (SFFQ) in a...
5.
6.
The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer
Cirne F, Aghel N, Petropoulos J, Klotz L, Lenihan D, Saad F, et al.
Eur Heart J Cardiovasc Pharmacother
. 2021 Jan;
8(3):253-262.
PMID: 33470403
Aims: The aim of this study was to determine whether gonadotropin-releasing hormone (GnRH) antagonists (an emerging class of drugs to suppress testosterone synthesis in the treatment of prostate cancer) cause...
7.
8.
Leong D, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, et al.
J Urol
. 2020 Jan;
203(6):1109-1116.
PMID: 31899651
Purpose: We describe the cardiovascular risk profile in a representative cohort of patients with prostate cancer treated with or without androgen deprivation therapy. Materials And Methods: We prospectively characterized in...
9.
Guo Y, Pinthus J, Bakker D, Davies B
Can Urol Assoc J
. 2019 Nov;
14(4):139-140.
PMID: 31702545
No abstract available.
10.
Li J, Tu H, Avram R, Pinthus J, Bordeleau L, Hodgson N
Breast J
. 2018 Jul;
24(6):1112-1113.
PMID: 30036902
No abstract available.